The role of low-dose aspirin in the prevention of colorectal cancer

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL. 1, 2012, Pages

  Avivi, Doran ^a   Moshkowitz, Menachem ^a   Detering, Elmar ^b   Arber, Nadir ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b BAYER PHARMA AG   (Germany)

Author keywords

Alzheimer's disease; Colorectal cancer; COX 2 inhibition; Low dose aspirin

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CELECOXIB; DICLOFENAC; IBUPROFEN; PLACEBO;

CANCER CELL CULTURE; CARDIOVASCULAR DISEASE; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; REVIEW; RISK FACTOR;

AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS;

EID: 84857608400     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.647810     Document Type: Review

References (86)

1. World Health Organization. Available from: http://www.who.int/ mediacentre/factsheets/fs297/en/[Last accessed 5 July 2011]
2. Nodora JN, Martz WD, Ashbeck EL, et al. Primary care physician compliance with colorectal cancer screening guidelines. Cancer Causes Control 2011;22:1277-87
3. Taylor DP, Cannon-Albright LA, Sweeney C, et al. Comparison of compliance for colorectal cancer screening and surveillance by colonoscopy based on risk. Genet Med 2011;13:737-43
4. Hoffman RM, Rhyne RL, Helitzer DL, et al. Barriers to colorectal cancer screening: physician and general population perspectives, New Mexico, 2006. Prev Chronic Dis 2011;8:A35
5. Bretthauer M. Colorectal cancer screening. J Intern Med 2011;270:87-98
6. Hawk ET, Limburg PJ, Viner JL. Epidemiology and prevention of colorectal cancer. Surg Clin North Am 2002;82:905-41 (Pubitemid 35463075)
7. Arber N. Cyclooxygenase-2 inhibitors in colorectal cancer prevention. Cancer Epidemiol Biomarkers Prev 2008;17:1852-7
8. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008;134:21-8 (Pubitemid 350309311)
9. Larsson SC, Giovannucci E, Wolk A. Long-term aspirin use and colorectal cancer risk: a cohort study in Sweden. Br J Cancer 2006;95:1277-9 (Pubitemid 44658496)
10. Flossmann E, Rothwell PM; on behalf of the British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369:1603-13 (Pubitemid 46710123)
11. Rothwell PM, Wilson M, Elwin C-E, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50
12. Mahipal A, Anderson KE, Limburg PJ, et al. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2006;15:1785-90 (Pubitemid 44664249)
13. Allison M, Garland C, Chlebowski R, et al. The association between aspirin use and the incidence of colorectal cancer in women. Am J Epidemiol 2006;164:567-75 (Pubitemid 44412785)
14. Sturmer T, Buring JE, Lee IM, et al. Colorectal cancer after start of nonsteroidal anti-inflammatory drug use. Am J Med 2006;119:494-502 (Pubitemid 43795185)
15. Jacobs EJ, Thun MJ, Bain EB, et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007;99:608-15 (Pubitemid 47073542)
16. Frils S, Poulsen AH, Sørensen HT, et al. Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study. Cancer Causes Control 2009;20:731-40
17. Ruder EH, Laiyemo AO, Graubard BI, et al. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol 2011;106:1340-50
18. Hoffmeister M, Chang-Claude J, Brenner H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer in a population-based case-control study. Int J Cancer 2007;121:1325-30 (Pubitemid 47293801)
19. Din FVN, Theodoratou E, Farrington SM, et al. Effect of aspirin and NSAIDS on risk and survival from colorectal cancer. Gut 2010;59:1670-9
20. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313-16 (Pubitemid 18042841)
21. Farrell B, Godwin J, Richards S, et al. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-54
22. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-59
23. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-41
24. The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-9
25. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6
26. Fuchs C, Meyerhardt JA, Heseltine DL, et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from Intergroup trial CALGB 89803. J Clin Oncol 2005;23(Suppl 16S):3530
27. Rothwell PM, Fowkes GR, Belch JFF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31-41
28. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9 (Pubitemid 36297997)
29. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90 (Pubitemid 36297996)
30. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003;125:328-36 (Pubitemid 36929412)
31. Logan RF, Grainge MJ, Shepherd VC, et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008;134:29-38 (Pubitemid 350309319)
32. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009;101:256-66
33. Burn J, Gerdes A-M, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011;378:2081-7
34. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002;99:13926-31 (Pubitemid 35215482)
35. Hahn E, Kraus S, Arber N. Role of cyclooxygenase-2 in pathogenesis and prevention of colorectal cancer. Dig Dis 2010;28:585-9
36. Honn KV. Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clin Exp Metastasis 1983;1:103-14 (Pubitemid 13029503)
37. Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001;61:1733-40 (Pubitemid 34292612)
38. Moreira L, Castells A. Cyclooxygenase as a target for colorectal cancer chemoprevention. Curr Drug Targets 2011;12:1888-94
39. Nakanishi Y, Nakatsuji M, Seno H, et al. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis 2011;32:1333-9
40. Nasir A, Lopez A, Boulware D, et al. Correlation between COX-2 and APC expression in left versus right-sided human colon cancer. Anticancer Res 2011;31:2191-5
41. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. Cancer Prev Res 2009;2:310-21
42. Arber N, Spicak J, Racz I, et al. Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol 2011;106:1135-46
43. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-42 (Pubitemid 47010839)
44. Peng J, Jian-qiu S, Ying-hui Z, et al. Expression of cyclooxygenase-2 and its relationship with mismatch repair and microsatellite instability in hereditary nonpolyposis colorectal cancer. Chin Med Sci J 2010;25:206-10
45. Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res 2011. [Epub ahead of print]
46. Ruschoff J, Dietmaier W, Bocker T, et al. Molecular cancer disposition diagnosis exemplified by colorectal carcinoma. What is the contribution of pathology? Pathologe 1998;19:269-78 (Pubitemid 28377526)
47. Schror K. Acetylsalicyclic acid. Wiley-Blackwell. WILEY-VCH Verlag GmbH & Co. KGaA; Weinheim, Germany: 2009
48. Borthwick GM, Johnson AS, Partington M, et al. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J 2006;20:2009-16 (Pubitemid 44953901)
49. Martinez ME, O'Brien TG, Fultz KE, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci USA 2003;100:7859-64 (Pubitemid 36760060)
50. Babbar N, Gerner EW, Casero RA Jr. Induction of spermidine/spermine N1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. Biochem J 2006;394:317-24 (Pubitemid 43259681)
51. Goel A, Chang DK, Ricciardiello L, et al. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res 2003;9:383-90 (Pubitemid 36109756)
52. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010;10:489-503
53. Ulrych T, Bohm A, Polzin A, et al. Release of sphingosine-1-phosphate from human platelets is dependent in thromboxane formation. J Thromb Haemost 2011;9:790-8
54. Voutsadakis IA, Patrikidou A, Tsapakidis K, et al. Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib. Int J Colorectal Dis 2010;25:795-804
55. De Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 2002;45:1588-94 (Pubitemid 35471007)
56. Huang K, Gutierrez LP, Bulow S, et al. Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study. Fam Cancer 2011;10:303-8
57. Driver JA, Gaziano M, Gelber RP, et al. Development of a risk score for colorectal cancer in men. Am J Med 2007;120:257-63 (Pubitemid 46341164)
58. Yeoh K-G, Ho K-Y, Chiu H-M, et al. The Asia-Pacific Colorectal Screening score: a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asia subjects. Gut 2011;60:1236-41
59. Leshno M, Moshkowitz M, Arber N. Aspirin is clinically effective in chemoprevention of colorectal neoplasia: point. Cancer Epidemiol Biomarkers Prev 2008;17:1558-61
60. Kim BJ, Kim JY, Chang DK, et al. Coexistence between carotid artery stenosis and colorectal adenomatous polyps in middle-aged men. Digestion 2010;81:20-6
61. Larsson S, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005;97:1679-87 (Pubitemid 41672234)
62. Cheng I, Caberto CP, Lum-Jones A, et al. Type 2 diabetes risk variants and colorectal cancer risk: the Multiethnic Cohort and PAGE studies. Gut 2011;60:1703-11
63. Berster JM, Goke B. Type 2 diabetes mellitus as risk factor for colorectal cancer. Arch Physiol Biochem 2008;114:84-98 (Pubitemid 351998747)
64. Giouleme O, Diamantidis MD, Katsaros M. Is diabetes a causal agent for colorectal cancer? pathophysiological and molecular mechanisms. World J Gastroenterol 2011;17:444-8
65. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-41
66. Aleksandrova K, Boeing H, Jenab M, et al. Metabolic syndrome and risks of colon and rectal cancer: the European Prospective Investigation into Cancer and Nutrition Study. Cancer Prev Res (Phila) 2011;4:1873-83
67. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72 (Pubitemid 34073943)
68. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006;119:624-38 (Pubitemid 44128438)
69. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321:1183-7
70. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):234S-64S (Pubitemid 39297956)
71. Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use: an update. Stroke 2005;36:1801-7 (Pubitemid 41098782)
72. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: recommendation statement. Ann Intern Med 2009;150:396-404
73. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 2011;34(Suppl 1):S11-61
74. Guerreiro RJ, Baquero M, Blesa R, et al. Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol Aging 2010;31:725-31
75. Bond J, Graham N, Padovani A, et al. Screening for cognitive impairment, Alzheimer's disease and other dementias: opinions of European caregivers, payors, physicians and the general public. J Nutr Health Aging 2010;14:558-62
76. Meyer JS, Rogers RL, McClintic K, et al. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc 1989;37:549-55 (Pubitemid 19135928)
77. Etminan M, Gill S, Samil A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003;327:128
78. Bentham P, Gray R, et al. AD2000 Collaborative Group. Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial. Lancet Neurol 2008;7:41-9
79. Richard E, Gouw AA, Scheltens P, et al. Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: the evaluation of vascular care in Alzheimer's disease (EVA) study. Stroke 2010;41:554-6
80. Thoonsen H, Richard E, Bentham P, et al. Aspirin in Alzheimer's disease: increased risk of intracranial hemorrhage: cause for concer? Stroke 2010;41:2690-2
81. Newton JL. Improving the gastrointestinal tolerability of aspirin in older people. Clin Interv Aging 2006;1:33-9
82. Ciabattoni G, Porreca E, Di Febbo C, et al. Determinants of platelet activation in Alzheimer's disease. Neurobiol Aging 2007;28:336-42 (Pubitemid 46177381)
83. Pomponi M, Di Giola A, Bria P, et al. Fatty aspirin: a new perspective in the prevention of dementia of Alzheimer's type. Curr Alzheimer Res 2008;5:422-31
84. Hassan C, Rex DK, Cooper GS, et al. Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis. Gut 2011. [Epub ahead of print]
85. Ladabaum U, Chopra CL, Huang G, et al. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2001;135:769-81 (Pubitemid 33051261)
86. Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology 2002;122:78-84 (Pubitemid 34049197)